To Homepage

Select your language

Die Inhalte dieser Seite sind auch auf Deutsch verfügbar.

Auf Deutsch ansehen
Our Commitment Progressing the potential of nucleic acids for a healthier world
We Are The Nucleic Acid Company

Who We Are

We are driven by our desire for a healthier world.
Restoring hope in patients living with debilitating diseases is our daily motivation to progress novel nucleic acid-based therapies to their commercial promise.  

BioSpring is a leading industry expert in nucleic acid science and technology, specializing in high-quality cGMP manufacturing and analytics for commercial programs and clinical phases I - III, in addition to preclinical material supply and diagnostic manufacturing. We are a privately owned company of over 600 employees committed to providing expert support through all phases and regulatory filings, including highly flexible and customizable solutions to accelerate therapeutic programs through the entire drug development lifecycle.

Headquartered in the center of Europe, in Frankfurt, Germany, we are an international company with a subsidiary in the United States and a local presence in Japan. Our global clients can rely on our quality and expertise, guided by our passion for innovation and three decades of experience. Our aim is a highly collaborative partnership to unleash the full potential of our clients’ technology, making great strides and breakthroughs possible. 

Moving the Elements of Life

What We Do

Today, BioSpring is one of the world's leading Contract Development and Manufacturing Organizations (CDMOs) for nucleic acid manufacturing and analytics. We serve pharma and biotech companies as well as academic institutions around the globe, supporting our clients with nucleic acid services from early discovery to commercial and diagnostic manufacturing.

We have also established ourselves as the leading clinical and commercial partner for cell and gene therapies, manufacturing high quality, custom guide RNA for genome editing applications.

Our products and services uphold the highest standards of quality and precision. We employ advanced technology and innovative processes and methods utilizing state-of-the-art facilities that are regularly audited and inspected by our industry-leading clients and regulatory authorities.

Did you know? In 2007, we became the first nucleic acid CDMO in Europe to become cGMP-certified. Learn more about our quality

What are oligonucleotides?

Oligonucleotides are short, synthetically manufactured nucleotide sequences with a length of approx. 2 to 200 bases. They consist of the same building blocks as DNA and RNA, which form the basis of our genetic information. Synthetic oligonucleotide-based therapeutic approaches offer targeted and personalized treatment options to patients worldwide. Their versatility allows for applications across many therapeutic fields, such as gene therapy, RNA interference, CRISPR/Cas9 gene editing, and antisense oligonucleotide therapies, focusing on diseases that are currently considered incurable. Oligonucleotides are also utilized in bioanalysis, diagnostics, forensics, and as vaccine adjuvants.


The BioSpring Team

Our clients' needs are our top priority. Through a highly collaborative partnership, we will help you accelerate your therapies to meet your therapeutic promise and give patients hope sooner. Combining client-focused solutions with innovation, efficiency, and quality enables us to successfully execute projects of any scale to the utmost satisfaction.

With our growing, international team, we continue to develop every day in order to consistently offer the best services to our clients. 


Our employees are highly trained and qualified across all departments and demonstrate an exceptional commitment to excellence. The collective strength of our culturally diverse teams and unparalleled expertise makes it possible for us to push the boundaries of what is achievable in our field, delivering servies that stand as a testament to our dedication and innovation.

History | A significant milestone 2020 Commercial Manufacturing

As an active pharmaceutical ingredient (API) supplier for an oligonucleotide drug that has now received approval, we were inspected by the FDA and successfully became a commercial manufacturer of oligonucleotide APIs.

History | Expansion of capabilities 2016 FDA Inspection & First Therapeutic Batch for CRISPR/Cas9

In 2016, we completed our first FDA pre-approval inspection for an analytical oligonucleotide program with no 483s. In addition, we successfully manufactured the first cGMP single-guide RNA (sgRNA) batch for CRISPR/Cas9.

History | First Worldwide 2014 Next-Generation OligoProcess Platform

We set a new industry standard by being the first worldwide to have selected and installed the Next-Generation OligoProcess synthesizer platform. With our ability to go from pilot scale to full production scale on the same system, we revolutionized oligonucleotide manufacturing services.

History | Highest Quality Standards 2007 cGMP-Certified by the German Authorities

In 2007, we became the first CDMO in Europe to be cGMP-certified by the German authorities for the manufacture and quality control of therapeutic oligonucleotides. In the same year, a client conducted the first clinical trial with one of our products.

History | New Paths 2000 Moving to Our Innovation Campus

To adress the growing demand for oligonucleotides worldwide, we boosted our production capabilities and chose an ideal location with excellent chemical infrastructure. On our innovation campus we equipped the new facilities with state-of-the-art technology and manufacturing equipment to optimally map production processes.

History | Foundations 1997 A Company with Scientific Roots

During their doctoral studies at the Goethe-Universität-Frankfurt, founders Dr. Sylvia Wojczewski and Dr. Hüseyin Aygün noticed a gap in the supply of high-quality oligonucleotides needed for research, development and therapy. This sparked their vision of founding a high-quality oligo company in Spring 1997 – and capturing that moment as part of our company’s name.

A success Story

Our Leadership

Dr. Sylvia Wojczewski and Dr. Hüseyin Aygün are the founders and managing directors of this owner-managed company. They co-founded BioSpring back in 1997 while completing their doctoral studies in chemistry at Goethe University in Frankfurt, and have led the company to become one of the largest manufacturers of synthetic nucleic acids in the world. It is their tremendous dedication to research, professionalism, and agility that has led BioSpring to this level of success. Alongside clients, Dr. Wojczewski and Dr. Aygün have the unwavering ambition to fully harness the potential of nucleic acids for global human health.

Portrait Aygün Wojczewski 1